Four things to know:
1. The bill would require infants born in the state to be tested for genetic markers linked with SMA.
2. SMA is a rare genetic disease that leads to progressive muscle weakness and, in some cases, paralysis.
3. The FDA approved AveXis’ $2.1 million gene therapy drug Zolgensma for SMA in May, which The Washington Post reported to be the most expensive drug in the world.
4. The Senate returned a unanimous vote of 36-0 on the bill.
More articles on spine:
Johns Hopkins, Carrum partnership grows to spine surgery
New York spine surgeon sentenced to probation, house arrest — 4 insights
11 PE transactions in orthopedics in 2019
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
